Biomed 101
From Self-sufficiency
 | This article provides insufficient context for those unfamiliar with the subject. Please help improve the article with a good introductory style. (January 2008) |
Biomed 101 is an agent binding to the leukotriene B4 receptor. This leads to reduced levels of interleukin-2 mediated hypoxia. Biomed 101 does not affect interleukin-2 antitumor activity.
Biomed 101 is also in the process of being tested to see if it can help reduce the side effects of a drug called interleukin-2 (IL-2), already it has been found that Biomed 101 does not affect interleukin-2 antitumor activity meaning these two drugs can work to gather safely if the anti-side effect property is found within Biomed 101[citation needed].
External links
Categories:
- Wikipedia articles needing context from January 2008
- Articles with invalid date parameter in template
- All Wikipedia articles needing context
- Wikipedia introduction cleanup from January 2008
- All pages needing cleanup
- All articles with unsourced statements
- Articles with unsourced statements from April 2009
- Drugs
- Cancer treatments
- Oncology
- Chemotherapeutic adjuvants
- 2Fix
